^
Association details:
Biomarker:IFNG expression
Cancer:Urothelial Cancer
Drug Class:PD-L1 inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

The expression panel of CXCL9, GBP5, and IFNG is a potential pan-cancer biomarker to predict immunotherapy response

Published date:
07/12/2023
Excerpt:
The expression of CXCL9, IFNG, and GBP5 was independently associated with the response to anti-PD-L1 immunotherapy in patients with mUC.